Stratus has secured two patents for its RF multitined expandable electrode, which the company says will protect the technology as procedural protocols shift from traditional radiofrequency ablation (RFA) needles to the Nimbus device.
The first patent granted, named System and Methods for Tissue Ablation, was issued on 21 July 2020, and the second, Methods and Systems for Spinal Radio Frequency Neurotomy, was issued soon after, on 11 August 2020.
Bret Boudousquie, Stratus Medical CEO, said: “We are pleased to secure these new patents to protect our proprietary Nimbus technology as procedural protocols shift from traditional RFA needles to the Nimbus device, which provides a large volume lesion with the goal to improve patient outcomes.”
Boudousquie adds that the company sees an “opportunity to help patients suffering from chronic pain and improve quality of life as interventional pain medicine physicians expand their utilisation of RFA to treat pain in the spine, knee and sacroiliac joint.”
Stratus Medical’s newest patents collectively contain 146 claims directed to radiofrequency systems. These claims provide broad protection for Stratus Medical’s Nimbus technology.
Stratus Medical now holds two US patents and 14 patents outside the USA on this technology, in addition to two patent applications pending in the USA and a further 10 patent applications pending outside of the country.